Table 2 Initial BV and Anti-PD-1 Therapy.

From: Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers

 

Brentuximab Vedotin

 

Anti-PD-1

 

n = 173

 

n = 173

Prior LOT (median, range)

2 (0–7)

Prior LOT (median, range)

3 (0–12)

Regimen

 

Regimen

 

 BV

105 (60.7)

Anti-PD-1

134 (77.4)

 BV + Chemo

43 (24.9)

Anti-PD-1 + Chemo

2 (1.2)

 BV + Anti-PD-1

25 (14.4)

BV + Anti-PD-1

25 (14.5)

  

Other Combination

12 (6.9)

Best Response

 

Best Response

 

 CR

37 (21.4)

CR

32 (18.5)

 PR

60 (34.7)

PR

63 (36.4)

 SD

21 (12.1)

SD

33 (19.1)

 PD

45 (26.0)

PD

37 (21.4)

 Unknown

10 (5.8)

Unknown

8 (4.6)

PFS (days, median, 95% CI)

166 (138–187)

PFS (days, median, 95% CI)

225 (179–265)

  1. Treatment characteristics for initial brentuximab vedotin and anti-PD-1 therapy.
  2. BV Brentuximab Vedotin, LOT Lines of Therapy, Chemo Chemotherapy, CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive Disease, PFS Progression Free Survival, CI Confidence Interval.
Back to article page